By sharing this link, I acknowledge that I have read and understand the Terms and Conditions.
50.9 MB (1.2 MB compressed)
3653 x 4870 pixels
31.0 x 41.1 cm ⏐ 12.2 x 16.2 in (300dpi)
RAMON ANDRADE 3DCIENCIA / SCIENCE PHOTO LIBRARY RAMON ANDRADE 3DCIENCIA / SCIENCE PHOTO LIBRARY
Illustration showing Aducanumab (purple, lower left), a human-derived monoclonal immunoglobulin G (IgG) antibody binding to amyloid beta plaques (blue and yellow). Amyloid beta plaques are insoluble aggregates of amyloid beta protein. They are believed to be linked to Alzheimer's disease by causing nerve cell death and affecting nerve cell signalling pathways. Aducanumab binds to amyloid beta plaques by targeting an epitope found on the amyloid beta protein. This causes a reduction in beta amyloid plaques in the brain. This could potentially slow down Alzheimer's disease progression, particularly patients in the earlier stages of the disease. On 7th of June 2021, Aducanumab was approved for treatment in Alzheimer's disease by the US Food and Drug Administration (FDA) through its accelerated approval pathway.
Model release not required. Property release not required.